Moderna Inc. (MRNA) is experiencing a significant surge in its stock price, driven by its upcoming re-entry into the Nasdaq-100 index.
Moderna's stock is rising today, up 7.31% to close at CA$211.41, following the announcement that it will rejoin the Nasdaq-100 index. This marks a major milestone for the biotech company, which had previously been removed from the index in December 2024 due to a decline in market value.
Advertisement
Moderna Inc
MRNA.US
MRNA.US
Moderna Inc
WealthAwesomeMarket cap
$78.65B
52W high
$212.22
52W low
$22.28
1W change
+4.27%
Beta
1.09
Analyst Price Targets
Based on 23 analysts covering MRNA · as of Oct 8, 2026
Wall Street analysts forecast MRNA stock price to fall 38.6% over the next 12 months.
Consensus
Hold3.17 / 5.00
Avg. Target
C$121.00
-38.6% Upside
Previously C$120.67 on Oct 5, 2026
Current Price
C$197.00
Last close
Analyst Breakdown (23 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on MRNA's historical volatility
30-Day Vol
74.5%
Annualized
90-Day Vol
194.0%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$235.52
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$209.08 | C$161.68 – C$270.38 |
| 60 trading days | C$221.91 | C$154.26 – C$319.21 |
| 90 trading days | C$235.52 | C$150.88 – C$367.63 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: The re-inclusion into the Nasdaq-100 is expected to attract institutional investment, potentially driving further demand for Moderna's shares as funds adjust their portfolios to include the stock.
7.31% Increase in Stock Value
Moderna's stock has surged significantly, reflecting a strong recovery and renewed investor interest following its upcoming Nasdaq-100 inclusion.
Bull case
The positive momentum around Moderna is supported by recent advancements in its mRNA technology, especially in cancer therapies, which have shown promising results in clinical trials. The company's market capitalization has jumped to $78.44 billion, indicating renewed investor confidence.
Bear case
Despite the impressive rise in stock price, Moderna still faces challenges, such as negative profit margins and a dependence on future pipeline developments to maintain its valuation. Current financial metrics show that the company has not yet returned to profitability, raising concerns about its long-term sustainability.
Rejoining the Nasdaq-100
Advertisement
Moderna's stock is set to rejoin the Nasdaq-100 index on October 9, replacing Warner Bros. Discovery. This change is primarily driven by the company's significant recovery in market value, which has increased by 571.42% over the past year. The Nasdaq-100 is known for including large-cap growth companies, and Moderna's inclusion is seen as a testament to its evolving business prospects beyond its initial focus on COVID-19 vaccines.
Positive Developments in mRNA Technology
Recent advancements in Moderna's mRNA technology, particularly in cancer therapies, have boosted investor confidence. The company has reported positive phase III results for its personalized cancer therapy developed in collaboration with Merck, which met key clinical endpoints. This progress has not only improved the company's market outlook but also solidified its position as a leader in the biotech sector.
Financial Metrics and Future Outlook
While Moderna's stock performance has been impressive, the company's financial metrics reveal ongoing challenges. With a negative profit margin and reliance on future product pipeline success, investors remain cautious about the sustainability of its current valuation. The upcoming months will be critical as Moderna seeks to translate its stock gains into tangible financial performance.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
